Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pro-DexPDEX -0.03%69 Days Sales Outstanding is 85.44 as of Mar. 2026, which is 31% above its 10-year median of 65.33. GuruFocus rates PDEX with a GF Score™ of 69/100 and a GF Value™ of $40.81 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 810 Medical Devices & Instruments companies, Pro-Dex ranks worse than 71.73% on this metric.
Pro-Dex's average Accounts Receivable for the
three
months ended in Mar. 2026 was $18.68 Mil. Pro-Dex's Revenue for the
three
months ended in Mar. 2026 was $19.95 Mil.
Hence, Pro-Dex's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 85.44.
The historical rank and industry rank for Pro-Dex's Days Sales Outstanding or its related term are showing as below:
PDEX'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.38 Med: 65.33 Max: 114.24
Current: 85.96
During the past 13 years, Pro-Dex's highest Days Sales Outstanding was 114.24. The lowest was 47.38. And the median was 65.33.
PDEX's Days Sales Outstanding is ranked worse than 71.73% of 810
companies
in the Medical Devices & Instruments industry
Industry Median: 65.455
vs PDEX: 85.96
Pro-Dex's Days Sales Outstanding
declined
from Mar. 2025 (89.94) to Mar. 2026 (85.44).
Pro-Dex (NAS:PDEX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Pro-Dex Days Sales Outstanding Related Terms
Pro-Dex Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Pro-Dex's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDEX vs KRMD, EMBC, UTMD: Days Sales Outstanding Comparison
For the Medical Instruments & Supplies subindustry, Pro-Dex's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro-Dex Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pro-Dex's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Pro-Dex's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pro-Dex (PDEX) has a Days Sales Outstanding of 85.44 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Pro-Dex and its competitors. This is 31% above median its historical median of 65.33. Over the past decade, Pro-Dex's Days Sales Outstanding has ranged from 47.38 to 114.24. According to the industry distribution chart, Pro-Dex ranks #581 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 71.7%.
Is Pro-Dex's Days Sales Outstanding too high?
Pro-Dex's current Days Sales Outstanding of 85.44 is 31% above median its 10-year median of 65.33. Over the past 10 years, this metric has ranged from a low of 47.38 to a high of 114.24. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.46. Pro-Dex's value of 85.44 is 30.5% above this industry median. Based on the distribution chart, Pro-Dex ranks #581 out of 810 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Pro-Dex has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pro-Dex's Days Sales Outstanding compare to KRMD and EMBC?
According to the Medical Devices & Instruments industry distribution chart, Pro-Dex ranks #581 out of 810 companies for Days Sales Outstanding. This places Pro-Dex in the lower half of its industry. The industry median Days Sales Outstanding is 65.46. Pro-Dex's value of 85.44 is 30.5% above this benchmark. Historically, Pro-Dex's own Days Sales Outstanding has ranged from 47.38 to 114.24 over the past decade. While the company's 10-year median is 65.33 vs. the industry median of 65.46, Pro-Dex has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.46, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro-Dex's current Days Sales Outstanding of 85.44 is 30.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Pro-Dex and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro-Dex's current Days Sales Outstanding is 85.44, which is 31% above median its own 10-year median of 65.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro-Dex stock overvalued right now?
Based on GuruFocus' analysis, Pro-Dex (PDEX) is currently considered Significantly Overvalued. The stock's GF Value™ is $40.81, compared to a current price of $66.76 — trading 63.6% above its estimated fair value. The current Days Sales Outstanding is 85.44, which is 31% above median its 10-year median of 65.33 and 30.5% above the Medical Devices & Instruments industry median of 65.46. Pro-Dex's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Pro-Dex (PDEX), the current Days Sales Outstanding is 85.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro-Dex (PDEX) Overvalued in 2026?
Based on GuruFocus' analysis, Pro-Dex stock appears to be overvalued.
The current stock price of $66.76 is trading 63.6% above its estimated GF Value™ of $40.81.
GuruFocus considers Pro-Dex to be Significantly Overvalued.
Key valuation signals for PDEX:
Days Sales Outstanding: 85.44 (31% above median its 10-year median of 65.33)
GF Value™: $40.81 vs. price of $66.76 (63.6% above fair value)
Industry Position: 30.5% above the Medical Devices & Instruments median (#581 of 810)
No single metric tells the full story. See the PDEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
69GF Score
Get the complete analysis for PDEX
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PDEX has been successfully added to your 
